Embracing the Pros and Cons of the New Weight Loss Medications (Semaglutide, Tirzepatide, Etc.)

被引:4
|
作者
Moyad, Mark A. [1 ]
机构
[1] Univ Michigan, Med Ctr, Dept Urol, Ann Arbor, MI 48109 USA
关键词
Semaglutide; Tirzepatide; Urology; GLP-1; agonist; Bariatric surgery; Lifestyle changes; Weight loss; BARIATRIC SURGERY; ENERGY-INTAKE; OBESITY; REDUCTION; EFFICACY; ADULTS; LIRAGLUTIDE; METABOLISM; OVERWEIGHT; OUTCOMES;
D O I
10.1007/s11934-023-01180-7
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose of ReviewThe history of multiple weight loss medications has been a concerning paradox based on an increased cardiovascular risk despite significant reductions in adipose tissue and weight. A new class of weight loss medications could change this past narrative based on early preliminary results of cardiovascular risk (not events-still need to be determined) and weight reduction in non-diabetics that acutely competes with results achieved with bariatric surgery. The purpose of this review is to provide a comprehensive summary of the advantages and disadvantages of these newer medications, and how they could impact urology.Recent FindingsWeight loss of - 15 to - 20% compared to baseline has become plausible in the short-term and preliminary guidance to reduce acute and chronic adverse events are receiving attention. However, the cost, access, conflicts of interest, supply chain, life-long adherence issues, and the long-term diverse implications on mental and physical health when exposed to this class of medications (GLP-1 agonists) are unknown. The profound caloric reductions should also result in baseline or ongoing nutritional deficiency testing, and general and specific dietary recommendations, which could theoretically mimic some bariatric surgery pre- and post-surgical protocols but has yet to be studied. Regardless, the potential impact of these medicines within a variety of medical specialties needs clinical research.SummaryCurrent and future lifestyle interventions, dietary patterns, and medicines in the weight loss category need to be held to a paradigm whereby cardiovascular health should improve with significant weight loss without a negative impact on mental health. In urology, the ability to impact cancer risk, ED, FSD, incontinence, infertility, nephrolithiasis, and multiple other endpoints are plausible (based on bariatric surgery data) but need preliminary clinical research. Other medicines with a similar or even larger potential impact are in clinical trials, and thus, a concise overview for clinicians and researchers was needed for objective guidance. Currently, comprehensive lifestyle changes utilized with and without these medications continue to garner positive mental, physical, and legacy effects, which suggest that they are as necessary as ever in the treatment of the numerous conditions impacted by unhealthy weight gain.
引用
收藏
页码:515 / 525
页数:11
相关论文
共 35 条
  • [21] Performance of a Machine-Learning Gene Risk Score Biomarker to Predict Weight-Loss Response to Tirzepatide and Semaglutide
    Tama, Elif
    Fansa, Sima
    Anazco, Diego
    Rivera, Rene
    Ghusn, Wissam
    Cifuentes, Lizeth
    Acosta, Andres
    Hurtado, Maria D.
    DIABETES, 2024, 73
  • [22] Weight loss medications: A new Pandora's box?
    Mohan, Babu P.
    GASTROINTESTINAL ENDOSCOPY, 2024, 100 (05) : 928 - 929
  • [23] Medications and conditions associated with weight loss in patients prescribed semaglutide based on real-world data
    Powell, William
    Song, Xing
    Mohamed, Yahia
    Walsh, Dave
    Parks, Elizabeth J.
    McMahon, Tamara M.
    Khan, Mirza
    Waitman, Lemuel R.
    OBESITY, 2023, 31 (10) : 2482 - 2492
  • [24] Public health perspective on new weight loss medications
    Mytton, Oliver
    Head, Vicky
    Reckless, Ian
    BMJ-BRITISH MEDICAL JOURNAL, 2024, 384
  • [25] Discontinuing semaglutide after weight loss: strategy for weight maintenance and a possible new side effect
    Carris, Nicholas W.
    Wallace, Shawn
    DuCoin, Christopher G.
    Mhaskar, Rahul
    Stern, Marilyn
    Bunnell, Brian
    CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, 2024, 102 (06) : 391 - 395
  • [26] Model-based simulation of glycaemic effect and body weight loss when switching from semaglutide or dulaglutide to once weekly tirzepatide
    Urva, Shweta
    Levine, Joshua A.
    Schneck, Karen
    Tang, Cheng Cai
    CURRENT MEDICAL RESEARCH AND OPINION, 2024, 40 (04) : 567 - 574
  • [27] Weight loss: New medications, and managing the health of the overweight woman
    Solomon, HS
    JOURNAL OF WOMENS HEALTH & GENDER-BASED MEDICINE, 2002, 11 (03): : 312 - 312
  • [28] What's so bad about weight loss, blood chemistry effects, kidney toxicity, etc. in a modeled ecological receptor?
    Tannenbaum, LV
    HUMAN AND ECOLOGICAL RISK ASSESSMENT, 2001, 7 (06): : 1765 - 1767
  • [29] Weight loss medications in Canada - a new frontier or a repeat of past mistakes?
    Wharton, Sean
    Lee, Jasmine
    Christensen, Rebecca A. G.
    DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY, 2017, 10 : 413 - 417
  • [30] PROs in Tirzepatide-Treated Adults with Type 2 Diabetes in SURPASS-1 to-6 by Age, Gender, BMI, and Weight Loss
    Boye, Kristina
    Thieu, Vivian
    Dong, Wenxiu
    Williamson, Suzanne E.
    Sapin, Helene
    DIABETES, 2024, 73